- Home
- IBRX vs CSAN Comparison
IBRX vs CSAN Comparison
Compare IBRX & CSAN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IBRX | CSAN |
|---|---|---|
| Founded | 2014 | 1936 |
| Country | United States | Brazil |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Retail-Auto Dealers and Gas Stations |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 5.3B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | IBRX | CSAN |
|---|---|---|
| Price | $2.38 | $4.64 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 7 | 3 |
| Target Price | ★ $9.71 | $9.50 |
| AVG Volume (30 Days) | ★ 11.5M | 1.6M |
| Earning Date | 11-04-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $82,555,000.00 | ★ $7,988,294,917.00 |
| Revenue This Year | $667.18 | $272.90 |
| Revenue Next Year | $88.32 | $0.66 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 1025.95 | 2.13 |
| 52 Week Low | $1.83 | $3.80 |
| 52 Week High | $4.27 | $6.33 |
Technical Indicators
Market Signals| Indicator | IBRX | CSAN |
|---|---|---|
| Relative Strength Index (RSI) | 56.50 | 43.34 |
| Support Level | $2.17 | $4.70 |
| Resistance Level | $2.40 | $5.61 |
| Average True Range (ATR) | 0.15 | 0.23 |
| MACD | 0.03 | -0.05 |
| Stochastic Oscillator | 72.22 | 1.01 |
Price Performance
Historical ComparisonAbout IBRX ImmunityBio Inc.
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.
About CSAN Cosan S.A. ADS
Cosan SA engages in several services throughout the energy and logistics sectors. Its reportable segments are Raizen, Compass, Moove, Rumo, and Radar. It generates the majority of its revenue from Raizen which operates in the production, commercialization, origination, and trading of ethanol, bioenergy, resale, and trading of electricity, renewable sources, marketing, origination, and trading of sugar and fuels, and lubricant.